---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-087001"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:48:55.951296+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics Reports Q2 2024 Financial Results and Positive Phase 2 SHINE Trial Data

## Summary
- Phase 2 SHINE trial showed ~40% mean improvement in ADAS-Cog 11 vs placebo in mild-to-moderate Alzheimer's.
- Cash and equivalents $28.5M as of June 30, 2024; NIA grant funds remaining $57.3M.
- Net loss $7.0M for Q2 2024 vs $4.7M for Q2 2023.
- Topline results from SHIMMER study in DLB expected by year-end 2024.
- Company planning next phase of Alzheimer's development after SHINE results.

## SEC filing metadata
- accession: 0001104659-24-087001
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465924087001/0001104659-24-087001-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465924087001/tm2421054d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-087001
- JSON: https://secwatch.observer/filing/0001104659-24-087001.json
- Plain text: https://secwatch.observer/filing/0001104659-24-087001.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.